Skip to main content

Site notifications

Therapeutic Goods (Poisons Standard) (COVID-19 Treatment - Pfizer) (Nirmatrelvir and Ritonavir) Labelling Exemption 2022

Published

Related content

Help us improve the Therapeutic Goods Administration site